- Open Access
Inhibition of B16 melanoma growth and metastasis in C57BL mice by vaccination with a syngeneic endothelial cell line
© Yoshiura et al; licensee BioMed Central Ltd. 2009
- Received: 07 November 2008
- Accepted: 31 January 2009
- Published: 31 January 2009
Key role of angiogenesis in tumor growth and metastasis based on accumulating evidence and recent progress of immunotherapy have led us to investigate vaccine therapy targeting tumor angiogenesis.
C57BL/6J mice were vaccinated with a syngeneic endothelial cell line Tpit/E by subcutaneous injection once a week. Prior to ninth vaccination, the mice were challenged with B16/F10 melanoma cells by subcutaneous inoculation on the back for the tumor growth model or by tail venous injection for the lung metastasis model. Development of subcutaneous tumor and lung metastasis was monitored by computed tomography scanning, which enabled accurate evaluation with the minimized sacrifice of mice.
Vaccination with Tpit/E cells inhibited subcutaneous tumor growth and appearance of lung metastasis compared to control. Survival period was elongated in the Tpit/E vaccination in both of the two models. We also obtained hybridomas secreting specific antibodies to Tpit/E cells from a mouse vaccinated with the cells, indicating that specific immune response to the syngeneic endothelial cells was elicited.
These results suggest that vaccination with an autologous endothelial cell line may be effective against melanoma.
- Subcutaneous Tumor
- Endothelial Cell Line
- C57BL Mouse
- Tumor Challenge
Cancer immunotherapy has now gained importance as therapeutics especially for cancers resistant to surgery, chemotherapy or radiation therapy. Previously, we have shown that melanoma patients vaccinated with tumor lysate pulsed-dendritic cells elicited antibody response to carbonic anhydrase II of which expression was specific to tumor endothelial cells . Angiogenesis has been shown to play a key role in tumor growth and metastasis and new molecules targeting tumor angiogenesis have been discovered and coming into clinical use [2–5]. These findings have led us to investigate cancer vaccine therapy targeting tumor angiogenesis.
Efficacy of immunotherapy targeting known molecules associated in tumor angiogenesis such as VEGF , VEGFR-2 [7–10], FGF-2 , FGFR-1 , endoglin , Tie-2 , HP59 , survivin , matrix metalloproteinase , integrin beta3 , vascular endothelial-cadherin , angiomotin , and angiopoietin-2  have been reported. Many other immunogenic antigens associated in tumor angiogenesis remains to be explored for the relevance as a target of immunotherapy.
Immunotherapy targeting tumor vasculature appears to have advantages over conventional immunotherapy targeting cancer cells, as it is assumed that failure of antigen-presentation mechanism, decrease of antigenicity by frequent mutation seen in cancer cells do not occur in vascular endothelial cells and that access of effectors is much easier in targeting vascular endothelium. So far, several reports have shown that tumor growth and metastasis were inhibited by vaccination with whole endothelial cells in mice [22–24]. Among these reports, a syngeneic sinusoidal endothelial cell vaccine has been shown to be effective in BALB/c mice . In the present study, we tested an immortalized syngeneic endothelial cell line originated from C57BL mice as a vaccine for treatment of melanoma. Advantages in use of a cell line are as follows: proliferating cells in culture may share angiogenic antigens with tumor vascular endothelial cells , and a cell line is able to supply as many cells as necessary with ease. Here, we demonstrated that vaccination with a syngeneic endothelial cell line Tpit/E inhibited growth and metastasis of B16/F10 melanoma. We also obtained hybridomas secreting specific antibodies to Tpit/E cells from the vaccinated mouse to prove occurrence of the specific immune response to the syngeneic endothelial cells.
Cell lines and culture
B16/F10 melanoma and SP-2 myeloma cell lines were provided by Cell Resource Center for Biomedical Research Institute of Development, Aging and Cancer Tohoku University (Sendai, Japan), and cultured in RPMI-1640 (Invitrogen, Carlsbad, CA) with 10% fetal bovine serum (FBS; Thermo Trace Ltd, Melbourne, Australia), at 37°C in an atmosphere of 95% air and 5% CO2. Tpit/E vascular endothelial cell line derived from pituitary gland of temperature sensitive T-antigen transgenic mouse was provided by RIKEN BRC Cell Bank (Tsukuba, Japan), and cultured in HAMF12/DMEM (Invitrogen, Carlsbad, CA) with 10% horse serum (Nichirei, Tokyo, Japan) and 2.5% FBS, at 33°C.
C57BL/6J mice of six to eight weeks were purchased from Tokyo Laboratory Animals Science (Tokyo, Japan). For the subcutaneous tumor model, mice were inoculated with 1 × 105 melanoma cells suspended in 100 μl 50% Matrigel (BD Biosciences, Bedford, MA)/phosphate buffered saline (PBS) on the back. For the lung metastasis model, 1 × 105 melanoma cells suspended in 100 μl saline were injected in the tail vein. All studies involving mice were approved by the institute's Animal Study Committee.
Vaccination with fixed cells
Computed Tomography Scanning
Mice were anesthetized by intrapenetorial injection of 1 mg ketamine hydrochloride and 6.7 μg medetomidine hydrochloride per mouse and subjected to computed tomography scanning using LaTheta LCT-100A in-vivo CT scanner for small animals (Aloka, Tokyo, Japan). For the subcutaneous tumor model, cross-sectional CT scans were taken at 1 mm intervals. Tumor volume was calculated by integration of tumor area in each slice through the tumor by the attached software. For the lung metastasis model, cross-sectional CT scans were taken at 0.5 mm intervals for the whole lung.
Fusion of spleen cells harvested from a sacrificed mouse and myeloma cells was performed using Polyethylene Glycol 1500 (Roche, Penzberg, Germany) based on the manufacturer's instruction. Cells were cultured in S-Clone medium (Sanko Junyaku, Tokyo, Japan) supplemented with HAT-media supplement (Sigma-Aldrich Japan, Tokyo, Japan). Selected cell colonies were isolated and conditioned media were harvested and stored at -20°C until use.
Immunofluorescence of cultured cells
Cultured Tpit/E and B16/F10 cells were fixed with methanol, treated with 0.2% TritonX-100/PBS, washed with PBS, treated with 1% bovine serum albumin (BSA)/PBS, washed with PBS, and treated with the hybridoma-conditioned medium for 30 min at RT. After washing with 0.1% TritonX-100/PBS, 10 μg/mL fluorescein conjugated goat anti-mouse IgG (Chemicon International, MA) diluted in 1% BSA, 0.1% TritonX-100/PBS was applied. After washing with 0.1% TritonX-100/PBS for 3 times, cells were observed by fluorescence and phase contrast microscope. For positive media, immunostaining was repeated after blocking with 100 × diluted normal mouse serum in PBS for 30 min at RT to rule out the possibility of non-specific stickiness to endothelial cell surface molecules including IgG Fc receptors .
Correlation between two factors, difference between two groups and difference between survivals of two groups were evaluated by the chi-square analysis, the t-test and the Kaplan-Meier analysis respectively. P values less than 0.05 were considered statistically significant.
Inhibition of subcutaneous tumor growth by the Tpit/E vaccination
Inhibition of lung metastasis by the Tpit/E vaccination
Animals with lung metastases at day 14 post tumor challenge
mice with metastasis
mice without metastasis
Anti-endothelial cell specific antibody generated in a Tpit/E vaccinated mouse
So far, vaccination with endothelial cells has been shown to be effective in several mice models using xenogeneic endothelial cells [22, 24] and syngeneic endothelial cells . When considering therapeutic application to human, autologous cells may be preferable to avoid host reactions to allogeneic or xenogeneic components in the vaccine. In addition, autologous cell vaccine may have less possibility to induce pathologic autoimmunity due to the tolerance mechanism. However, preparation of a considerable amount of tumor vascular endothelial cells from an individual patient is almost impossible. Therefore, we tested the efficacy of a syngeneic endothelial cell line as a substitute. In addition, cell lines are expected to share characteristics with tumor vascular endothelial cells . These advantages may have contributed to anti-tumor effects on melanoma with high malignancy.
As for cancer models in the previous reports, employed were fibrosarcoma, hepatoma, mammary carcinoma , lung carcinoma [22, 24], myeloma , and colon carcinoma . It is noteworthy that our study showed for the first time the anti-tumor effect of an endothelial cell vaccine against B16/F10 melanoma in both of the subcutaneous tumor and the lung metastasis models. In the course of the subcutaneous tumor growth, occasional tumor necrosis in the Tpit/E vaccinated mice was observed, suggesting occurrence of vascular damage, though further studies are required. Once B16/F10 tumor was challenged, the tumor grew so rapidly and life span was within several weeks without therapy in the present study. Considering a time length required for immune response after vaccination, the anti-tumor effect seemed difficult to detect in a therapeutic setting such as vaccination after tumor challenge. However, anti-tumor effect in a therapeutic setting may be observed if challenged melanoma cells are reduced.
In this study, we aimed to prove that specific antibodies to Tpit/E cells were generated in the vaccinated mice. We thought that positive immunostaining of Tpit/E cells with sera of vaccinated mice may be insufficient because such sera may contain a variety of antibodies including ones against inoculated B16/F10 cells. Therefore, we isolated antibodies by making hybridomas and obtained some clones secreting antibodies reactive with Tpit/E but not with B16/F10 cells. It is obvious that tumor endothelium expresses specific molecules which are not expressed on normal vascular endothelium . Vaccination with Tpit/E cells may have targeted such antigens because vaccination with autologous molecules might not provoke effective immune reaction due to the tolerance. Xenogeneic cells or molecules have been widely employed as vaccines because they tend to break the tolerance [6, 10, 12, 14, 17, 18, 22, 24, 28]. To show that tumor endothelium specific molecules are targeted, we plan to identify antigen molecules recognized by isolated antibodies in the present study by a proteomics strategy . In addition, effects of the isolated antibodies on tumor vasculature including antibody-dependent cytotoxic activity and also the role of cellular immunity in the response to vaccination should be explored as CTL activities to vaccinated endothelial cells in other settings have been shown [23, 24].
To apply the vaccine therapy using an autologous endothelial cell line to human, development of the cell line from a patient is a next subject. Practically, culture of umbilical vein endothelial cells (HUVECs) on a close genetic background may be a good candidate. Recently, a pilot study of HUVECs vaccine in cancer patients with promising results in brain tumors but not in colorectal cancer was reported . No prominent adverse effect observed in the study may facilitate wider application of HUVECs vaccine to various cancers including melanoma. However, some tumor endothelium specific antigens are reported to appear in the vasculature of wound healing tissue , possible adverse effects of endothelial cell vaccine on wound healing remains to be clarified.
Vaccination with a syngeneic endothelial cell line Tpit/E inhibited subcutaneous tumor growth as well as appearance of lung metastasis and elongated survival period of C57BL mice challenged with B16/F10 melanoma, and elicitation of specific antibodies to Tpit/E cells was demonstrated.
This work was supported in part by the Ministry of Education, Culture, Sports, Science and Technology (MEXT), HAITEKU (2004–2008) and Musashino Joshigakuin Special Fund.
- Yoshiura K, Nakaoka T, Nishishita T, Sato K, Yamamoto A, Shimada S, Saida T, Kawakami Y, Takahashi TA, Fukuda H, Imajoh-Ohmi S, Oyaizu N, Yamashita N: Carbonic anhydrase II is a tumor vessel endothelium-associated antigen targeted by dendritic cell therapy. Clin Cancer Res. 2005, 11: 8201-8207.View ArticleGoogle Scholar
- Folkman J: What is the evidence that tumors are angiogenesis dependent?. J Natl Cancer Inst. 1990, 82: 4-6.View ArticleGoogle Scholar
- Scappaticci FA: Mechanisms and future directions for angiogenesis-based cancer therapies. J Clin Oncol. 2002, 20: 3906-3927.View ArticleGoogle Scholar
- Bergers G, Benjamin LE: Tumorigenesis and the angiogenic switch. Nat Rev Cancer. 2003, 3: 401-410.View ArticleGoogle Scholar
- Neri D, Bicknell R: Tumour vascular targeting. Nat Rev Cancer. 2005, 5: 436-446.View ArticleGoogle Scholar
- Wei YQ, Huang MJ, Yang L, Zhao X, Tian L, Lu Y, Shu JM, Lu CJ, Niu T, Kang B, Mao YQ, Liu F, Wen YJ, Lei S, Luo F, Zhou LQ, Peng F, Jiang Y, Liu JY, Zhou H, Wang QR, He QM, Xiao F, Lou YY, Xie XJ, Li Q, Wu Y, Ding ZY, Hu B, Hu M, Zhang W: Immunogene therapy of tumors with vaccine based on Xenopus homologous vascular endothelial growth factor as a model antigen. Proc Natl Acad Sci USA. 2001, 98: 11545-11550.View ArticleGoogle Scholar
- Niethammer AG, Xiang R, Becker JC, Wodrich H, Pertl U, Karsten G, Eliceiri BP, Reisfeld RA: A DNA vaccine against VEGF receptor 2 prevents effective angiogenesis and inhibits tumor growth. Nat Med. 2002, 8: 1369-1375.View ArticleGoogle Scholar
- Zhang L, Yu D, Hicklin DJ, Hannay JA, Ellis LM, Pollock RE: Combined anti-fetal liver kinase 1 monoclonal antibody and continuous low-dose doxorubicin inhibits angiogenesis and growth of human soft tissue sarcoma xenografts by induction of endothelial cell apoptosis. Cancer Res. 2002, 62: 2034-2042.Google Scholar
- Li Y, Wang MN, Li H, King KD, Bassi R, Sun H, Santiago A, Hooper AT, Bohlen P, Hicklin DJ: Active immunization against the vascular endothelial growth factor receptor flk1 inhibits tumor angiogenesis and metastasis. J Exp Med. 2002, 195: 1575-1584.View ArticleGoogle Scholar
- Liu JY, Wei YQ, Yang L, Zhao X, Tian L, Hou JM, Niu T, Liu F, Jiang Y, Hu B, Wu Y, Su JM, Lou YY, He QM, Wen YJ, Yang JL, Kan B, Mao YQ, Luo F, Peng F: Immunotherapy of tumors with vaccine based on quail homologous vascular endothelial growth factor receptor-2. Blood. 2003, 102: 1815-1823.View ArticleGoogle Scholar
- Plum SM, Holaday JW, Ruiz A, Madsen JW, Fogler WE, Fortier AH: Administration of a liposomal FGF-2 peptide vaccine leads to abrogation of FGF-2-mediated angiogenesis and tumor development. Vaccine. 2000, 19: 1294-1303.View ArticleGoogle Scholar
- He QM, Wei YQ, Tian L, Zhao X, Su JM, Yang L, Lu Y, Kan B, Lou YY, Huang MJ, Xiao F, Liu JY, Hu B, Luo F, Jiang Y, Wen YJ, Deng HX, Li J, Niu T, Yang JL: Inhibition of tumor growth with a vaccine based on xenogeneic homologous fibroblast growth factor receptor-1 in mice. J Biol Chem. 2003, 278: 21831-21836.View ArticleGoogle Scholar
- Takahashi N, Haba A, Matsuno F, Seon BK: Antiangiogenic therapy of established tumors in human skin/severe combined immunodeficiency mouse chimeras by anti-endoglin (CD105) monoclonal antibodies, and synergy between anti-endoglin antibody and cyclophosphamide. Cancer Res. 2001, 61: 7846-7854.Google Scholar
- Luo Y, Wen YJ, Ding ZY, Fu CH, Wu Y, Liu JY, Li Q, He QM, Zhao X, Jiang Y, Li J, Deng HX, Kang B, Mao YQ, Wei YQ: Immunotherapy of tumors with protein vaccine based on chicken homologous Tie-2. Clin Cancer Res. 2006, 12: 1813-1819.View ArticleGoogle Scholar
- Fu C, Bardhan S, Cetateanu ND, Wamil BD, Wang Y, Yan HP, Shi E, Carter C, Venkov C, Yakes FM, Page DL, Lloyd RS, Mernaugh RL, Hellerqvist CG: Identification of a novel membrane protein, HP59, with therapeutic potential as a target of tumor angiogenesis. Clin Cancer Res. 2001, 7: 4182-4194.Google Scholar
- Xiang R, Mizutani N, Luo Y, Chiodoni C, Zhou H, Mizutani M, Ba Y, Becker JC, Reisfeld RA: A DNA vaccine targeting survivin combines apoptosis with suppression of angiogenesis in lung tumor eradication. Cancer Res. 2005, 65: 553-561.Google Scholar
- Su JM, Wei YQ, Tian L, Zhao X, Yang L, He QM, Wang Y, Lu Y, Wu Y, Liu F, Liu JY, Yang JL, Lou YY, Hu B, Niu T, Wen YJ, Xiao F, Deng HX, Li J, Kan B: Active immunogene therapy of cancer with vaccine on the basis of chicken homologous matrix metalloproteinase-2. Cancer Res. 2003, 63: 600-607.Google Scholar
- Lou YY, Wei YQ, Yang L, Zhao X, Tian L, Lu Y, Wen YJ, Liu F, Huang MJ, Kang B, Xiao F, Su JM, He QM, Xie XJ, Mao YQ, Lei S, Liu JY, Lou F, Zhou LQ, Peng F, Jiang Y, Hu B: Immunogene therapy of tumors with a vaccine based on the ligand-binding domain of chicken homologous integrin beta3. Immunol Invest. 2002, 31: 51-69.View ArticleGoogle Scholar
- Liao F, Doody JF, Overholser J, Finnerty B, Bassi R, Wu Y, Dejana E, Kussie P, Bohlen P, Hicklin DJ: Selective targeting of angiogenic tumor vasculature by vascular endothelial-cadherin antibody inhibits tumor growth without affecting vascular permeability. Cancer Res. 2002, 62: 2567-2575.Google Scholar
- Holmgren L, Ambrosino E, Birot O, Tullus C, Veitonmaki N, Levchenko T, Carlson LM, Musiani P, Iezzi M, Curcio C, Forni G, Cavallo F, Kiessling R: A DNA vaccine targeting angiomotin inhibits angiogenesis and suppresses tumor growth. Proc Natl Acad Sci USA. 2006, 103: 9208-9213.View ArticleGoogle Scholar
- Oliner J, Min H, Leal J, Yu D, Rao S, You E, Tang X, Kim H, Meyer S, Han SJ, Hawkins N, Rosenfeld R, Davy E, Graham K, Jacobsen F, Stevenson S, Ho J, Chen Q, Hartmann T, Michaels M, Kelley M, Li L, Sitney K, Martin F, Sun JR, Zhang N, Lu J, Estrada J, Kumar R, Coxon A, Kaufman S, Pretorius J, Scully S, Cattley R, Payton M, Coats S, Nguyen L, Desilva B, Ndifor A, Hayward I, Radinsky R, Boone T, Kendall R: Suppression of angiogenesis and tumor growth by selective inhibition of angiopoietin-2. Cancer Cell. 2004, 6: 507-516.View ArticleGoogle Scholar
- Wei YQ, Wang QR, Zhao X, Yang L, Tian L, Lu Y, Kang B, Lu CJ, Huang MJ, Lou YY, Xiao F, He QM, Shu JM, Xie XJ, Mao YQ, Lei S, Luo F, Zhou LQ, Liu CE, Zhou H, Jiang Y, Peng F, Yuan LP, Li Q, Wu Y, Liu JY: Immunotherapy of tumors with xenogeneic endothelial cells as a vaccine. Nat Med. 2000, 6: 1160-1166.View ArticleGoogle Scholar
- Okaji Y, Tsuno NH, Kitayama J, Saito S, Takahashi T, Kawai K, Yazawa K, Asakage M, Hori N, Watanabe T, Shibata Y, Takahashi K, Nagawa H: Vaccination with autologous endothelium inhibits angiogenesis and metastasis of colon cancer through autoimmunity. Cancer Sci. 2004, 95: 85-90.View ArticleGoogle Scholar
- Chen XY, Zhang W, Wu S, Bi F, Su YJ, Tan XY, Liu JN, Zhang J: Vaccination with viable human umbilical vein endothelial cells prevents metastatic tumors by attack on tumor vasculature with both cellular and humoral immunity. Clin Cancer Res. 2006, 12: 5834-5840.View ArticleGoogle Scholar
- Walter-Yohrling J, Morgenbesser S, Rouleau C, Bagley R, Callahan M, Weber W, Teicher BA: Murine endothelial cell lines as models of tumor endothelial cells. Clin Cancer Res. 2004, 10: 2179-2189.View ArticleGoogle Scholar
- Pan L, Kreisle RA, Shi Y: Expression of endothelial cell IgG Fc receptors and markers on various cultures. Chin Med J (Engl). 1999, 112: 157-161.Google Scholar
- St Croix B, Rago C, Velculescu V, Traverso G, Romans KE, Montgomery E, Lal A, Riggins GJ, Lengauer C, Vogelstein B, Kinzler KW: Genes expressed in human tumor endothelium. Science. 2000, 289: 1197-1202.View ArticleGoogle Scholar
- Hou JM, Liu JY, Yang L, Zhao X, Tian L, Ding ZY, Wen YJ, Niu T, Xiao F, Lou YY, Tan GH, Deng HX, Li J, Yang JL, Mao YQ, Kan B, Wu Y, Li Q, Wei YQ: Combination of low-dose gemcitabine and recombinant quail vascular endothelial growth factor receptor-2 as a vaccine induces synergistic antitumor activities. Oncology. 2005, 69: 81-87.View ArticleGoogle Scholar
- Okaji Y, Tsuno NH, Tanaka M, Yoneyama S, Matsuhashi M, Kitayama J, Saito S, Nagura Y, Tsuchiya T, Yamada J, Tanaka J, Yoshikawa N, Nishikawa T, Shuno Y, Todo T, Saito N, Takahashi K, Nagawa H: Pilot study of anti-angiogenic vaccine using fixed whole endothelium in patients with progressive malignancy after failure of conventional therapy. Eur J Cancer. 2008, 44: 383-390.View ArticleGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.